CBT Stock Overview
Operates as a specialty chemicals and performance materials company.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 1/6 |
Past Performance | 6/6 |
Financial Health | 5/6 |
Dividends | 5/6 |
Cabot Corporation Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$86.00 |
52 Week High | US$95.00 |
52 Week Low | US$60.00 |
Beta | 1.26 |
11 Month Change | -7.53% |
3 Month Change | 1.18% |
1 Year Change | 40.98% |
33 Year Change | 75.51% |
5 Year Change | 105.67% |
Change since IPO | 289.14% |
Recent News & Updates
Recent updates
Shareholder Returns
CBT | DE Chemicals | DE Market | |
---|---|---|---|
7D | -2.8% | 1.3% | 0.8% |
1Y | 41.0% | 4.5% | 2.0% |
Return vs Industry: CBT exceeded the German Chemicals industry which returned 4.5% over the past year.
Return vs Market: CBT exceeded the German Market which returned 2% over the past year.
Price Volatility
CBT volatility | |
---|---|
CBT Average Weekly Movement | 3.7% |
Chemicals Industry Average Movement | 4.4% |
Market Average Movement | 4.8% |
10% most volatile stocks in DE Market | 10.3% |
10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: CBT has not had significant price volatility in the past 3 months.
Volatility Over Time: CBT's weekly volatility (4%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1882 | 4,268 | Sean Keohane | www.cabotcorp.com |
Cabot Corporation operates as a specialty chemicals and performance materials company. The company operates through two segments, Reinforcement Materials and Performance Chemicals. It offers reinforcing carbons that are used in tires as a rubber reinforcing agent and performance additive, as well as in industrial products, such as hoses, belts, extruded profiles, and molded goods; and engineered elastomer composites solutions.
Cabot Corporation Fundamentals Summary
CBT fundamental statistics | |
---|---|
Market cap | €4.74b |
Earnings (TTM) | €413.54m |
Revenue (TTM) | €3.65b |
11.5x
P/E Ratio1.3x
P/S RatioIs CBT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
CBT income statement (TTM) | |
---|---|
Revenue | US$3.91b |
Cost of Revenue | US$2.99b |
Gross Profit | US$923.00m |
Other Expenses | US$480.00m |
Earnings | US$443.00m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | 8.02 |
Gross Margin | 23.61% |
Net Profit Margin | 11.33% |
Debt/Equity Ratio | 78.6% |
How did CBT perform over the long term?
See historical performance and comparison